Bundle Blocks 1

Breast Cancer Awareness

October is Breast Cancer Awareness month. Breast cancer develops when healthy cells start to change and grow in an uncontrolled way. These cells usually form a mass called a tumor. Besides skin cancer, breast cancer is the most common type of cancer diagnosis for women in the United States. About 12% of U.S. women (or 1 in 8) will develop breast cancer in her lifetime. 

Our friends at SURVIVEiT have developed breast cancer resources that have been reviewed and approved as "best in class" by Team SURVIVEiT®'s medical and survivor advisory boards. Visit their breast cancer resources page to find related medical, financial, and support resources specific to breast cancer.

AI is Changing the Face of Medical Treatment

AI is Changing the Face of Medical Treatment

When you hear the term “artificial intelligence,” you might picture the evil AI overlords from The Matrix that feed on humans, or the androids in Blade Runner relegated to the dangerous task of interplanetary mining. These representations of AI are definitely entertaining, but Hollywood Sci-Fi movies have obscured the practical applications of AI in the real world.

Treating cancer involves a complexity of tests and expert analysis in order to determine the best course of action. Historically, these treatment plans have been developed based on a “one-size-fits-all” approach, without much consideration given to the genomic drivers of the individual’s particular type of cancer.

With new advancements in personalized medicine and cognitive computing, however, treatment therapies can now be tailored to a patient based on their individual genomic profile.

Two companies making improvements in efficiency and decision making in this area are Avera Health and Viviphi, Ltd.  

Identifying DNA Damage caused by TOP2 enzyme

Identifying DNA Damage caused by TOP2 enzyme

As a result of recent study of the DNA-cutting enzyme TOP2, scientists have created a tool that can identify specific sites of mutation across the entire genome of human leukemia cells.

The tool helps oncologists and researchers better understand the rearrangements that lead to leukemia, and will contribute to future developments in treatment.

Dacomitinib increases Survival Rates in Lung Cancer Patients

Dacomitinib increases Survival Rates in Lung Cancer Patients

Phase III clinical trials show promise in delaying the growth of cancer in patients with EFGR-positive non-small cell lung cancer with a new second generation targeted inhibitor, dacomitinib. Patients who received this new inhibitor over another inhibitor, gefitinib, had a 41% lower chance of cancer progression.

Viviphi and Avera Health Confirm Clinical Validation and System-Wide Implementation of the PrecisionPlan™ Cognitive Computing Platform

Viviphi and Avera Health Confirm Clinical Validation and System-Wide Implementation of the PrecisionPlan™ Cognitive Computing Platform

Viviphi Ltd (Greenwood Village, CO) and Avera Health (Sioux Falls, SD) announced today that the PrecisionPlan™ platform will be fully implemented across the multi-state cancer system. The platform was developed through a clinical collaboration in precision medicine between the two organizations. PrecisionPlan™ is a cognitive computing platform that generates comprehensive, actionable and patient-specific treatment plans in a matter of seconds. The artificial intelligence solution combines patient-specific diagnostic, surgical and demographic data from the electronic medical record (EMR) with genomic and tumor sequencing information to generate personalized treatment plans that comply with nationally respected evidence and the latest clinical guidance in precision medicine.

Viviphi Announces Appointment of Howard L. McLeod, PharmD, to the position of Senior Research Advisor in Precision Medicine and Member of Precision Medicine Advisory Board

Viviphi Announces Appointment of Howard L. McLeod, PharmD, to the position of Senior Research Advisor in Precision Medicine and Member of Precision Medicine Advisory Board

Viviphi Ltd (Greenwood Village, CO) announced the appointment of Dr. Howard McLeod, to the position of Senior Research Advisor in Precision Medicine.  McLeod will also join the Viviphi Precision Medicine Clinical Advisory Board.   He is well known to the Precision Medicine community given his leadership responsibilities for the Department of Individualized Cancer Management at the H. Lee Moffitt Cancer Center in Tampa Bay, Florida.

In his role with Viviphi, Dr. McLeod will assist in translating research and clinical advances in precision medicine in oncology.  He will help to drive the Viviphi™ technology roadmap and will function as an active ambassador of the Company and the PrecisionPlan™ cognitive computing platform at national and international research and clinical symposia.

Viviphi Appoints Pradip De, PhD, to the position of Director, Translational Oncology and Member of Precision Medicine Advisory Board

Viviphi Appoints Pradip De, PhD, to the position of Director, Translational Oncology and Member of Precision Medicine Advisory Board

Viviphi Ltd (Greenwood Village, CO) announced the appointment of Dr. Pradip De to the position of Director of Translational Oncology.   Dr. De is the Senior Scientist and Head of Translational Oncology at the Avera Cancer Institute Center for Precision Oncology. He holds the position of Assistant Professor in the Department of Internal Medicine at the University of South Dakota Sanford School of Medicine.

In his role with Viviphi, and in light of his superb comprehension of oncogenic signaling pathways, Dr. De will support the development, maintenance, testing and validation of sequence-guided oncology treatment rules. These codified clinical rules enable the translation of patient specific data into actionable knowledge for physicians to implement through the Viviphi™ cognitive computing platform known as PrecisionPlan™. Precision medicine in oncology is becoming a new standard of care in cancer medicine, and Viviphi has created a first-of-its-kind precision medicine planning platform that produces actionable and patient-specific treatment plans in real time.

Blood tests can be Used to Detect Cancer Early

Blood tests can be Used to Detect Cancer Early

A study shows that a new high intensity approach to genomic sequencing can locate circulating tumor DNA at a high rate in patients with advanced breast, lung and prostate cancer. Genetic changes found in tumor samples were also detected in blood samples with help of this new approach. Researchers will now use this technology in hopes of developing a new blood test to detect cancer early.

Breakthrough CAR-T cancer treatment provides 100% response rate for multiple myeloma

Breakthrough CAR-T cancer treatment provides 100% response rate for multiple myeloma

Success arises from a new cell and gene therapy for multiple myeloma – a blood cancer.

33 out of the 35 patients in a study responded positively and were in some level of remission within two months. In a second study of nearly two-dozen, everyone above a certain dose responded. “I can't say we may get a cure but at least we bring hope of that possibility," said Dr. Frank Fan. 

Experts at an American Society of Clinical Oncology conference in Chicago, where the results were announced Monday, say it's a first for multiple myeloma and rare for any cancer treatment to have such success.

The addition of Pertuzumab to traditional Trastuzumab may inhibit the development of invasive breast cancer

The addition of Pertuzumab to traditional Trastuzumab may inhibit the development of invasive breast cancer

A phase III clinical trial in a large sample of women with HER2-positive breast cancer suggests that post surgery patients who add a second HER2 targeted medicine, Pertuzumab, to standard of care, Tratuzumab, may show some modest benefits. Patients who were given a second drug had a 19% lower chance of developing invasive breast cancer.

Proper diet and exercise boosts cancer survival rates

Proper diet and exercise boosts cancer survival rates

Studies of colon and breast cancer patients show that those implementing routine diet and exercise programs into their lifestyle can result in prolonged life expectancies.  A colon cancer study showed patients with increased fruit and vegetable consumption, and reduced refined grain and meat consumption, combined with regular exercise had a 42% lower chance of death after seven years.  Similarly, a study of Australian breast cancer survivors had better survival rates with the addition of 180 minutes of exercise per week.

Avera Innovations in the Management of Cancer Conference – A Focus on Breast

Avera Innovations in the Management of Cancer Conference – A Focus on Breast

National and international experts will convene at Avera in Sioux Falls, South Dakota to discuss the latest techniques in breast cancer treatment.

Designed to provide surgeons, radiation oncologists and medical oncologists practice innovations from national and international experts on topics of electron based intra-operative radiation therapy, genomic targeted therapy and oncoplastic surgery techniques.

The conference will focus on the role of genomics, oncoplastic surgery techniques, electron-based intraoperative radiation therapy, neoadjuvant chemotherapy, and the future of surgery and radiation oncology. Attendees will include Surgeons, Radiation Oncologists, Medical Oncologists, and representatives from pharmaceuticals.

The course directors include Julie Reiland, MD, FACS, who specializes in breast cancer treatment and technology at Avera, and Brian Leyland-Jones, MB BS PhD, Vice President of Avera Cancer Institute for Precision Oncology and Vice President of Molecular and Experimental Medicine at Avera.

Precision Medicine World Conference

Precision Medicine World Conference

Dr. Howard McLeod from the Moffitt Cancer Center and Dr. Fred Ashbury, Chief Scientific Officer at Viviphi, will host a discussion on the challenges and lessons learned to implement a precision medicine program in oncology at the Precision Medicine World Conference at Duke University on Wednesday, May 24.

Session Synopsis: Precision Medicine (PM) leaders will discuss issues and lessons learned implementing PM programs as well as opportunities for community oncology practices. Topics include: requirements for creating a precision medicine program (personnel, supports); working with sequencing labs;interpreting results; and tools needed to scale and bring genomic-guided therapies to physicians and patients. A presentation of the PrecisionPlan™ oncology workbench to facilitate patient-specific genomic-guided treatment plans at point-of-care in real-time will support the discussion.

5 Healthcare Trends Impacting Cancer Care

5 Healthcare Trends Impacting Cancer Care

Precision medicine is revolutionizing how oncologists are treating cancer and is one of the top drivers changing cancer care today. Our PrecisionPlan™ platform is designed to help physicians navigate this change by providing physicians with immediate access to standards of care and expert knowledge on genomic-based therapies. Oncology professionals from community cancer centers discussed the changes at the annual ACCC (Association of Community Cancer Centers) meeting in Washington, D.C. 

Viviphi Ltd and Avera Health Announce a Strategic Collaboration Agreement for Precision Medicine

Viviphi Ltd and Avera Health Announce a Strategic Collaboration Agreement for Precision Medicine

DENVER — (December 15, 2016) — Viviphi Ltd and Avera Health (Sioux Falls, SD) announced today a first-of-its-kind clinical collaboration in precision medicine for oncology.  The strategic collaboration will combine Avera’s world leading position in evidence-based knowledge and practical application of genomic-based precision medicine for cancer patients with Viviphi’s patent pending Artificial Intelligence (“AI”) comprehensive clinical pathway and precision medicine planning platform.  Avera’s preeminent molecular cancer knowledge, along with nationally accepted standards of care, will be made accessible, in real time, to patients and treatment teams around the world via Viviphi’s AI-based OKaaS™ (Oncology Knowledge as a Service) platform.

Ipilimumab decreases chances of recurrence in Stage III Melanoma

Ipilimumab decreases chances of recurrence in Stage III Melanoma

Advanced melanoma patients who received adjuvant treatment with the checkpoint inhibitor (CTLA4) Ipilimumab had significantly increased overall survival, distant metastasis-free survival, and recurrence-free survival as compared with placebo, per a new study.

Medical Specialists can now More Accurately Test for Cervical Cancer

Medical Specialists can now More Accurately Test for Cervical Cancer

Johns Hopkins’ scientists have reported they have developed a urine test that predicts cervical cancer that is highly accurate compared to other tests based on genetic markers derived directly from cervical tissue. Not only does this particular urine test detect DNA changes from precancerous cells, it also detects the human DNA alterations from Human Papillomavirus (HPV), a sexually transmitted disease directly linked to cervical cancer.

Viviphi Ltd Unveils its New Comprehensive Precision Medicine Planning Platform

Viviphi Ltd Unveils its New Comprehensive Precision Medicine Planning Platform

New Platform Will Support Cancer Care Physicians in Meeting Oncology Care Model Participation Requirements

DENVER — (BUSINESS WIRE/December 14, 2016) — Viviphi Ltd announced today a first-of-its-kind comprehensive pathway and precision medicine planning platform which includes codified clinical rules in support of genomic-based targeted therapies, immunotherapies and complex combination treatments. The Viviphi™ platform will support participating cancer treatment providers with meeting The Center for Medicare and Medicaid Innovation’s (CMMI) new Oncology Care Model (OCM) requirements.  PrecisionPlan™ will be available to OCM participants in January 2017 as the 5-year value-based care funding pilot moves from the planning phase to implementation. 

Atezolizumab Increases Survival over Current Standard of Care

Atezolizumab Increases Survival over Current Standard of Care

Atezolizumab received FDA approval in October for the treatment of metastatic non-small cell lung cancer (NSCLC) patients with disease progression during or following platinum-containing therapy. The PD-L1 inhibitor atezolizumab (Tecentriq) provided a substantial overall survival benefit to patients with advanced non-small cell lung cancer, compared with standard chemotherapy.

Bringing Precision Medicine in Cancer into the Mainstream

Bringing Precision Medicine in Cancer into the Mainstream

Our comprehensive precision medicine planning platform has been "trained" to reach in and grab the relevant patient information and connect it to our clinical rules engine.

A Platform to Transform the Patient and Oncologist Experience

A Platform to Transform the Patient and Oncologist Experience

Imagine a world where your cancer treatment team can access your molecular pathology results and align them with the latest evidence and clinical guidance.

Changing the Conversation about Cancer

Changing the Conversation about Cancer

Learn about the best available treatment options for your specific cancer, including genomic-guided targeted therapies and immunotherapies.

Cancer Care and Business Experts Form Viviphi Ltd

Cancer Care and Business Experts Form Viviphi Ltd

Seasoned Cancer Care and Business Experts Come Together to Form Viviphi Ltd to Accelerate Consumer and Physician Adoption of Genomic Based Care Approaches